Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: Curr Pharm Des. 2017 Nov 16;23(29):4226–4246. doi: 10.2174/1381612823666170616082125

Table 2.

Targeted therapy for IGF-1R

Inhibitor Target Types of cancer
IMC-A12 (Cixutumumab) [50, 51] IGF-1R Advanced nonsquamous NSCLC, metastatic docetaxel-pretreated castration-resistant prostate cancer
CP-751, 871 (Figitumumab) [52] IGF-1R Advanced solid tumor
MK-0646 (Dalotuzumab) [53, 54] IGF-1R Advanced solid tumor, KRAS wild-type, metastatic colorectal cancer
AMG 479 (Ganitumab) [55, 56] IGF-1R Mutant KRAS metastatic colorectal cancer, metastatic adenocarcinoma of the pancreas
R1507 [57] IGF-1R Recurrent or refractory rhabdomyosarcoma, osteosarcoma, dynovial sarcoma, other soft tissue sarcoma
SCH-717454 (Robatumumab) [58] IGF-1R Relapsed osteosarcoma and Ewing sarcoma
AVE1642 [59, 60] IGF-1R Advanced solid tumor
MEDI-573 [61, 62] IGF-1R and IGF-2 Advanced solid tumor